Removable Walker for Neuropathic Ulcers

Sponsor
IRCCS Multimedica (Other)
Overall Status
Completed
CT.gov ID
NCT01005264
Collaborator
(none)
48
1
2
12.9
3.7

Study Details

Study Description

Brief Summary

  1. Objective: To evaluate the efficacy of removable cast walker compared to non-removable fiberglass off-bearing cast in the treatment of diabetic plantar foot ulcer

  2. Research design and methods: Forty-five adult diabetic patients with non-ischemic, non-infected neuropathic plantar ulcer were randomized to treatment with a non-removable fiberglass off-bearing cast (TCC group) or walker cast (Stabil-D group). Treatment duration was 90 days. Percent reduction in ulcer surface area and total healing rates were evaluated after treatment.

Condition or Disease Intervention/Treatment Phase
  • Device: non-removable fiberglass
  • Device: Stabil-D®
Phase 3

Detailed Description

Study design:

Two centers specializing in diabetic foot management (located in Sesto S. Giovanni and Milan, Italy) participated to this open, randomized clinical trial. The ethics-committee approved the study on January 10th, 2008. Enrollment of consecutive patients began February 2008 and ended March 2009. Eligible patients were fully informed of the study aim and procedures and written consent was obtained prior to study participation. Patients were then randomly assigned to one of the two treatment groups by opening randomization codebreak envelopes containing one of the two options. Separate randomization was performed for each center, and a copy of all randomization envelopes was kept at the statistical department of the Multimedica center. The two arms were composed of patients managed with non-removable fiberglass off-bearing cast (TCC group) and patients offloaded with the Stabil-D® (Podartis srl, Montebelluna, Treviso, Italy) walker cast (Stabil-D group).

Study Design

Study Type:
Interventional
Actual Enrollment :
48 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Removable Walker Cast Versus Non-removable Fiberglass Off-bearing Cast in the Healing of Diabetic Plantar Foot Ulcer- a Randomized Controlled Trial
Study Start Date :
Feb 1, 2008
Actual Primary Completion Date :
Mar 1, 2009
Actual Study Completion Date :
Mar 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: non-removable fiberglass

Softcast3M®, 3M Health Care, St. Paul, MN (USA) were used for construction of the pressure-relief apparatus

Device: non-removable fiberglass
Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
Other Names:
  • Softcast3M®, 3M Health Care, St. Paul, MN (USA)
  • Active Comparator: Stabil-D®

    Composed of a specifically designed rigid, boat shaped, and fully rocker bottom sole

    Device: Stabil-D®
    Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
    Other Names:
  • Podartis srl, Montebelluna, Treviso, Italy
  • Outcome Measures

    Primary Outcome Measures

    1. Decrease in ulcer size [at 90th day]

    Secondary Outcome Measures

    1. Complete healing rate at the end of the study [at 90th day]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • The presence of neuropathic plantar ulcer with an area graded IA according to the Texas University classification, AND

    • The presence of peripheral neuropathy. Peripheral neuropathy was diagnosed based on insensitivity to a 10-g Semmes-Weinstein monofilament in more than 6 out of 9 areas of the foot and by a vibration perception threshold measured by biothesiometer (Neurothesiometer SLS, Nottingham, UK) at the malleolus > 25 volts.

    Exclusion Criteria:
    • Presence of an ankle-brachial pressure index (ABI) < 0.9 and/or transcutaneous oxygen tension (TcPO2) < 50 mmHg tested on the dorsum of the foot,

    • Presence of clinical signs of infection, including edema, erythema, increased local skin temperature, or drainage,

    • The probe-to-bone maneuver was required to be negative,

    • Tthe standard X-ray examination of the foot was required to be negative for osteomyelitis,

    • Use of steroids or cytostatic drugs,

    • Presence of sensory, motor, or visual problems that could impair functional autonomy,

    • Active ulcer on the contralateral foot,

    • Previous major amputation of the contralateral limb,

    • Previous or current deep venous leg thrombosis, OR

    • Mental disorders interfering with patient compliance.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Diabetic Foot Center - IRCCS Multimedica Sesto San Giovanni Milan Italy 20099

    Sponsors and Collaborators

    • IRCCS Multimedica

    Investigators

    • Principal Investigator: Ezio Faglia, MD, Diabetic Foot Center - IRCCS Multimedica, Sesto San Giovanni (Milan), Italy

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01005264
    Other Study ID Numbers:
    • 05/2007cardiovascolare
    First Posted:
    Oct 30, 2009
    Last Update Posted:
    Oct 30, 2009
    Last Verified:
    Oct 1, 2009

    Study Results

    No Results Posted as of Oct 30, 2009